Want to see IMDX full AI Analyst Report?
IMDX Stock Chart & Stats
$3.17
--
Market closed
$3.17
--
Day’s Range― - ―
52-Week Range$2.33 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$152.09M
Enterprise Value$87.36
Total Cash (Recent Filing)$28.20M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.50Price Target Upside231.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.15M
Bulls Say, Bears Say
Bulls Say
Regulatory Progress — FDA SubmissionAn active FDA submission and reported productive engagement materially reduces regulatory execution risk and is core to U.S. commercialization. Successful review enabling initial instrument placements and orders would create a durable revenue channel, support payer contracting, and de-risk future market expansion.
Quality System Certification (ISO 13485)ISO 13485 certification establishes a regulated quality system essential for medical device manufacturing and global market entry. It lowers operational and regulatory friction for commercial scale-up, supports contract manufacturing, and strengthens credibility with customers and regulators long-term.
Established Medicare ReimbursementA clear Medicare reimbursement benchmark provides a durable pricing anchor and monetization path in the U.S. It aids ASP validation, payer negotiations, and hospital adoption economics, improving the structural revenue model and supporting long-term unit economics once volumes scale.
Bears Say
Severely Weak Financial PerformanceSteep revenue decline and a negative TTM gross margin indicate the business is far from break-even. Persistent operating cash flow deficits (TTM OCF ~ -$24M; FCF ~ -$26.8M) mean the company cannot self-fund growth, raising reliance on external capital and execution risk over the medium term.
Negative Stockholders' EquityNegative equity signals accumulated losses and weak net capital structure, which constrains financing options and increases dilution risk from future equity raises. This structural weakness can limit ability to secure debt, negotiate supplier terms, or fund commercialization without significant shareholder dilution.
High Near-Term Cash Burn Vs. Minimal RevenueA peak quarterly burn combined with immaterial near-term revenue creates a structural runway constraint. Elevated spend tied to regulatory and commercialization programs, plus instrument-placement limits on sales, increases likelihood of near-term financing needs and slows ability to scale margins and revenues sustainably.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.33 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $152.09M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 19 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.142.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,290,170 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 25.882%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (231.23% Upside)
$10.50 (231.23% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
380.80%
Trailing 12-Months
Asset Growth
-33.02%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
IMDX Stock 12 Month Forecast
Average Price Target
$10.50
▲(231.23% Upside)
Technical Analysis
Ownership Overview
79.85% Insiders
2.28% Mutual Funds
0.57% Other Institutional Investors
14.92% Public Companies and
Individual Investors